'This is a great opportunity to help people': Poolbeg on mission to enhance cancer treatment

Poolbeg’s lead drug promises to curb a dangerous side effect of cutting-edge cancer immunotherapies

Poolbeg Pharma chief executive Jeremy Skillington. Listed in London, Poolbeg is in preparation for a pivotal clinical trial to take place in the UK next year. 

At the centre of Ireland’s vibrant biotechnology scene, Cork native Jeremy Skillington is leading Poolbeg Pharma’s charge to transform cancer treatment.

The company is in preparation for a pivotal clinical trial to take place in the UK next year. Poolbeg’s lead drug, POLB 001, promises to curb a dangerous side effect of cutting-edge cancer immunotherapies, potentially allowing patients to receive life-saving treatments closer to home.